Odonate (Odonate) Change In Working Capital : $-0.13 Mil (TTM As of Sep. 2021)

View and export this data going back to 2017. Start your Free Trial

What is Odonate Change In Working Capital?

Odonate's change in working capital for the quarter that ended in Sep. 2021 was $-2.16 Mil.

Odonate's change in working capital for the fiscal year that ended in Dec. 2020 was $2.44 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Odonate Change In Working Capital Historical Data

The historical data trend for Odonate's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Odonate Change In Working Capital Chart

Odonate Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Working Capital

Get a 7-Day Free Trial

0.29

1.87

14.73

2.68

2.44

Odonate Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Change In Working Capital	Get a 7-Day Free Trial															2.53	-1.79	6.44	-2.63	-2.16

Odonate Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Odonate Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Odonate's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Odonate (Odonate) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Odonate Inc (OTCPK:ODTCD) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 East 28th Street, 10th Floor, New York, NY, USA, 10016

Website

https://www.odonate.com

Odonate Inc is a Shell company.

Executives

Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Boxer Capital, Llc	director, 10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Kevin C Tang	director, 10 percent owner, officer: Chief Executive Officer	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Aaron I. Davis	director, 10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Michael S Hearne	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Joseph P O'connell	officer: Chief Medical Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Boxer Asset Management Inc.	10 percent owner	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Robert Rosen	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Joseph Lewis	10 percent owner	PO BOX N7776, LYFORD BAHAMAS
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
John G Lemkey	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121